Guardant Health EBIT

: $-397.9 Mil (TTM As of Mar. 2022)

View and export this data going back to 2018. Start your Free Trial

Guardant Health's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2022 was $-122.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2022 was $-397.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Guardant Health's annualized ROC % for the quarter that ended in Mar. 2022 was -40.89%. Guardant Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -150.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Guardant Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -7.76%.

Guardant Health EBIT Historical Data

The historical data trend for Guardant Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

-80.51

-82.97

-68.54

-241.14

-381.89

Guardant Health Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EBIT																-106.60	-96.85	-106.79	-71.66	-122.61

Guardant Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-397.9 Mil.

Guardant Health (NAS:GH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Guardant Health's annualized ROC % for the quarter that ended in Mar. 2022 is calculated as:

	ROC % (Q: Mar. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2021 )	+	Invested Capital (Q: Mar. 2022 ))	/ count )
=	-493.352 * ( 1 - 0.02% )	/	( (1235.051	+	1177.602)	/ 2 )
=	-493.2533296	/	1206.3265
=	-40.89 %

where

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2204.499	-	50.009	-	( 932.748	-	max(0, 194.687	-	1114.126	+	932.748	))
=	1235.051

	Invested Capital		(Q: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2129.598	-	67.525	-	( 962.266	-	max(0, 228.809	-	1113.28	+	962.266	))
=	1177.602

Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Guardant Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2021		Q: Mar. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-490.432	/	( ( (313.904 + max(-0.4530000000001, 0))	+	(339.929 + max(-61.239, 0)) )	/	2 )
=	-490.432	/	( ( 313.904	+	339.929 )	/	2 )
=	-490.432	/	326.9165
=	-150.02 %

where Working Capital is:

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(97.652	+	30.674	+	53.052)	-	(50.009	+	11.326	+	120.496)
=	-0.4530000000001

	Working Capital		(Q: Mar. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(84.331	+	36.613	+	30.07)	-	(67.525	+	10.57	+	134.158)
=	-61.239

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Guardant Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2022 )
	=	-397.899	/	5129.084
	=	-7.76 %

Guardant Health EBIT Related Terms

Thank you for viewing the detailed overview of Guardant Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health Business Description

Industry

Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071

Comparable Companies

NAS:NTRA NAS:OCDX NAS:LNTH NAS:MEDP NAS:NEOG NAS:OPK NAS:TWST NAS:SHC NAS:MYGN NAS:FLGT NYSE:TMO NYSE:DHR XSWX:LONN SHSE:603259 NYSE:IQV NAS:ILMN NYSE:A NAS:IDXX NYSE:MTD NYSE:LH

Traded in Other Exchanges

GH:Mexico 5GH:Germany

Address

505 Penobscot Drive, Redwood City, CA, USA, 94063

Website

https://www.guardanthealth.com

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Executives

Talasaz Amirali	director, officer: Chairman, President and COO	18 ISABELLA AVENUE ATHERTON CA 94027
Kaul Samir	director	C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025
Meresman Stanley J	director	2071 HUNTINGTON LANE LOS ALTOS CA 94024
Svf Bluebird (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Svf Enterprise (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Sb Investment Advisers (uk) Ltd	10 percent owner	69 GROSVENOR STREET LONDON X0 W1K 3JP
Softbank Vision Fund (aiv M1) L.p.	10 percent owner	251 LITTLE FALLS DRIVE WILMINGTON DE 19808
Svf Endurance (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Clark Ian T	director	SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Eltoukhy Helmy	director, officer: Chief Executive Officer	2 BARRY LANE ATHERTON CA 94027
Bertocci Derek A	officer: Chief Financial Officer	3070 ORCHARD DRIVE SAN JOSE CA 95134
Saia John G.	officer: See Remarks	C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063
Gadde Vijaya	director	C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103
Jallal Bahija	director	120 MONUMENT CIRCLE INDIANAPOLIS IN 46204
Nishar Dipchand	director	C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043

Guardant Health Headlines

From GuruFocus

Study Shows Guardant360� Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer

By Business Wire 11-11-2021

Guardant Health Receives Medicare Coverage for Guardant360 TissueNext� Test

By Business Wire 03-08-2022

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

By Business Wire 11-04-2021

Guardant Health Appoints Myrtle Potter to Its Board of Directors

By Business Wire 10-20-2021

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR�-2 Blood Test to Detect Colorectal Cancer

By Business Wire 12-17-2021

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

By Business Wire 08-05-2021

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal� Blood Test to Predict Recurrence Across Early-Stage Cancers

By Business Wire 10-05-2021

Other Sources

$GH - Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation. Guardant Health Inc 2021 Q4 Results Earnings Call Presentation

By Seekingalpha 2022-02-24

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Data

Economic Indicators

By Country

Articles

Submit Articles

Guardant Health EBIT

Guardant Health EBIT Historical Data

Guardant Health EBIT Calculation

Guardant Health EBIT Related Terms

Guardant Health Business Description

Guardant Health Headlines

Guardant Health to Report Third Quarter Financial Results on November 4, 2021

Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference

Guardant Health to Participate in the 2021 Stifel Healthcare Conference

Study Shows Guardant360� Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer

Guardant Health Receives Medicare Coverage for Guardant360 TissueNext� Test

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

Guardant Health Appoints Myrtle Potter to Its Board of Directors

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR�-2 Blood Test to Detect Colorectal Cancer

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal� Blood Test to Predict Recurrence Across Early-Stage Cancers

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

Why Guardant Health Jumped Nearly 5% on Tuesday

$GH - Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q3 2021 Results - Earnings Call Transcript.…

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

$GH - Guardant Health (GH) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference.…

$GH - Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation. Guardant Health Inc 2021 Q4 Results Earnings Call Presentation

CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales

$GH - Taking A Gander At Guardant Health. Taking A Gander At Guardant Health

Why Guardant Health Is Down More Than 14% Friday

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Why Guardant Health Stock Soared Nearly 10% Higher Today

Why Guardant Health Stock Zoomed 10% Higher Today

Charles River (CRL) to Report Q4 Earnings: What's in Store?

Leerink Partners Sticks to Their Buy Rating for Guardant Health (GH)

Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline